Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease
Copyright © 2019 Elsevier Inc. All rights reserved..
Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:214 |
|---|---|
| Enthalten in: |
The Journal of pediatrics - 214(2019) vom: 24. Nov., Seite 227-230 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Oda, Takuya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comparative Study |
|---|
| Anmerkungen: |
Date Completed 21.05.2020 Date Revised 21.05.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jpeds.2019.06.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299633675 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299633675 | ||
| 003 | DE-627 | ||
| 005 | 20231225100747.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jpeds.2019.06.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0998.xml |
| 035 | |a (DE-627)NLM299633675 | ||
| 035 | |a (NLM)31351682 | ||
| 035 | |a (PII)S0022-3476(19)30712-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Oda, Takuya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.05.2020 | ||
| 500 | |a Date Revised 21.05.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Inc. All rights reserved. | ||
| 520 | |a Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a concentration | |
| 650 | 4 | |a fever duration | |
| 650 | 4 | |a intravenous immunoglobulin | |
| 650 | 4 | |a preparation | |
| 650 | 4 | |a treatment-related adverse event | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 700 | 1 | |a Nagata, Hazumu |e verfasserin |4 aut | |
| 700 | 1 | |a Nakashima, Yasutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Nanishi, Etsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Takada, Yui |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Manao |e verfasserin |4 aut | |
| 700 | 1 | |a Kubo, Eiji |e verfasserin |4 aut | |
| 700 | 1 | |a Hatae, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Ohga, Shouichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of pediatrics |d 1945 |g 214(2019) vom: 24. Nov., Seite 227-230 |w (DE-627)NLM000019003 |x 1097-6833 |7 nnns |
| 773 | 1 | 8 | |g volume:214 |g year:2019 |g day:24 |g month:11 |g pages:227-230 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jpeds.2019.06.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 214 |j 2019 |b 24 |c 11 |h 227-230 | ||